Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

Physician’s Weekly – 11/03/2024 –The following is a summary of “Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience,” published in the December 2023 issue of Hematology by Thurlapati et al.

Researchers started a retrospective study to assess the impact of high-risk cytogenetic abnormalities (HRCAs) on outcomes after high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) for newly diagnosed multiple myeloma (NDMM) patients.

They involved 449 patients with NDMM who received HDT-ASCT (February 2012 and August 2022). HRCAs, comprising deletion 17p, t(14;16), t(4;14), and amplification 1q, were assessed. Kaplan-Meier estimator was employed to analyze survival outcomes, including PFS and OS.

The results showed a median follow-up of 29 (1 – 128) months. Patients with HRCAs had a lower overall response rate than those with standard-risk cytogenetics (90% vs. 96%; P=0.01). Patients with HRCAs experienced inferior PFS (29 vs. 58 months; P<0.001) but no significant difference in OS (70 months vs. not reached; P=0.13).

Investigators concluded that HRCAs, non-lenalidomide maintenance, and older age were linked to worse PFS; only non-lenalidomide maintenance was related to worse OS.

Source: thejh.org/index.php/jh/article/view/1201

Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.

©2024 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.



Posted on 19 March 20248 April 2024